New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
05:49 EDTCCXIChemoCentryx CCX168 shows improvement in BVAS
ChemoCentryx reported additional Phase II data related to CCX168, an orally administered inhibitor that targets the receptor for the complement protein known as C5a, or C5aR. Data from the first two steps of the CLEAR trial show that patients receiving CCX168 showed improvements in the Birmingham Vasculitis Activity Score, or BVAS, an overall disease activity index, including efficacy observed in both the renal and the non-renal components of the BVAS. BVAS response at 12 weeks was higher in patients on CCX168 than those patients receiving the standard of care. BVAS remission (a higher threshold that is thought to require 24 weeks of treatment or longer for maximum effect) at 12 weeks was comparable to standard of care. Both non-renal and renal disease components of BVAS were improved in patients on CCX168 treatment. Additionally, as previously reported, patients treated with CCX168 as compared to standard of care showed greater improvements in renal function based on renal disease activity measurements including estimated glomerular filtration rate, urinary albumin:creatinine ratio, and urinary monocyte chemoattractant protein-1:creatinine ratio.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:39 EDTCCXIChemoCentryx reports CCX507 well tolerated, effective in Phase I study
Subscribe for More Information
October 20, 2014
08:37 EDTCCXIChemoCentryx releases Phase III SHIELD 4 clinical results
ChemoCentryx reported data from the Phase III SHIELD 4 clinical trial in Crohn's disease with vercirnon, an inhibitor of the chemokine receptor known as CCR9. Data showed that patients experienced improved response and remission rates when taking a higher dose of vercirnon. There was no evidence of higher gastrointestinal, hepatic, or cardiovascular adverse events with the twice daily group compared to the once daily group. Thomas J. Schall, Ph.D., president and CEO stated, "These SHIELD 4 data are consistent with our earlier positive PROTECT-1 study data. As with PROTECT-1, the data indicate that vercirnon is safe and well tolerated in patients with Crohn's disease, and there is a dose-dependent improvement in symptoms in the observed patient population in SHIELD 4. The Phase III drug CCX282/vercirnon, in addition to our second-generation, Phase II-ready CCR9 inhibitor, CCX507, provide a strong complement of drugs in our CCR9 program for which we intend to find a strategic partner."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use